India is poised for a major shift in weight-loss treatment as the patent for semaglutide—the molecule behind Novo Nordisk’s Wegovy and Ozempic—expires this Friday. The move will allow Indian pharmaceutical companies to produce cheaper generics, potentially halving current prices and expanding access nationwide.
Investment bank Jefferies described it as a potential “magic-pill moment” for India, projecting the semaglutide market could reach $1 billion domestically if pricing and uptake align. Analysts predict roughly 50 branded generics could enter the market within months, mirroring the surge seen when diabetes drug sitagliptin went off patent in 2022.
Semaglutide, a GLP-1 receptor agonist initially developed to treat diabetes, has emerged as a highly effective weight-loss treatment. By mimicking a hormone that regulates appetite and blood sugar, the drug helps patients feel full sooner and maintain satiety longer.
Major Indian drugmakers—including Cipla, Sun Pharma, Dr Reddy’s Laboratories, Biocon, Natco, Zydus, and Mankind Pharma—are preparing to launch branded generics.
Monthly costs, currently between 8,800 and 16,000 rupees ($95–$173), could fall to 3,000–5,000 rupees ($36–$54). Experts say lower prices could transform the anti-obesity drug market, which has grown from $16 million in 2021 to nearly $100 million in 2025.
India faces high demand for weight-loss solutions, with more than 77 million people living with type-2 diabetes and one of the largest populations of overweight adults globally. Cheaper GLP-1 drugs could aid treatment across medical specialties—from endocrinology to cardiology, orthopaedics, and sleep medicine.
However, experts caution that the drugs are not risk-free. Side effects can include nausea, vomiting, digestive issues, gallstones, or pancreatitis.
Rapid weight loss without proper diet or exercise may also lead to muscle loss. Doctors emphasize careful patient selection, gradual dosing, and lifestyle modifications to ensure safe and effective outcomes.
Concerns remain over potential misuse. As generics become widely available, unregulated prescriptions by gym trainers, dieticians, or online pharmacies could increase.
Authorities have warned against direct-to-consumer advertising that promises dramatic results, stressing that these medicines should only be used under medical supervision.
Despite these challenges, physicians are optimistic. Cheaper semaglutide could make effective weight-loss treatment accessible to millions in India and, potentially, abroad. Dr. Rahul Baxi, a Mumbai-based diabetologist, says he is already preparing to prescribe the drug to patients once prices drop after March 20.
